文献速递免疫规划传染病防控与疫情报告

NDV-3A疫苗预防金黄色葡萄球菌定植的2期随机对照试验

Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees.
PubMed 文献 · Vaccine · 2021-05-04

在美国陆军步兵训练学员中开展2期随机双盲安慰剂对照试验,评估单剂NDV-3A疫苗预防金黄色葡萄球菌鼻腔和口腔定植的安全性与效力。疫苗反应原性轻微并可诱导抗原特异性B细胞和T细胞应答,但接种后56天内鼻腔定植发生率在疫苗组与安慰剂组间无差异(25.6% vs 29.1%,VE 12.1%,p=0.31)。

要点

  • 单剂NDV-3A安全性良好,可诱导抗原特异性B细胞和T细胞应答。
  • 接种后56天鼻腔金葡菌定植率疫苗组25.6%、安慰剂组29.1%,差异无统计学意义。
  • 口腔定植效力同样不佳(VE 2.4%,p=0.52),未达预防定植目标。

核心结论

  • 单剂NDV-3A未能预防高危军事训练学员的鼻腔或口腔金黄色葡萄球菌定植。

研究设计与样本

  • 2期随机双盲安慰剂对照试验,纳入美国陆军步兵训练学员,入营72小时内肌注单剂NDV-3A或安慰剂,14周训练周期内纵向采集鼻腔和口腔拭子。

主要发现

  • 疫苗反应原性轻微并诱导抗原特异性B细胞和T细胞应答。
  • 接种后56天鼻腔定植发生率疫苗组25.6%、安慰剂组29.1%(VE 12.1%,p=0.31)。
  • 无定植间期分析两组无差异(VE 13%,p=0.29)。
  • 口腔定植效力不佳(VE 2.4%,p=0.52)。

关键数值与推荐

  • 鼻腔定植:25.6% vs 29.1%,VE 12.1%,p=0.31。
  • 无定植间期:VE 13%,p=0.29。
  • 口腔定植:VE 2.4%,p=0.52。

临床怎么用

  • 本研究结果不支持将单剂NDV-3A用于军事训练人群金黄色葡萄球菌定植的预防。
  • 金黄色葡萄球菌疫苗研发仍需探索其他抗原或免疫策略。

局限性

  • 原文未报告样本量、置信区间及长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Military trainees are at increased risk for Staphylococcus aureus colonization and infection. Disease prevention strategies are needed, but a S. aureus vaccine does not currently exist. METHODS: We enrolled US Army Infantry trainees (Fort Benning, GA) in a phase 2, randomized, double-blind, placebo-controlled trial of NDV-3A, a vaccine containing a recombinant adhesin/invasion protein of Candida albicans that has structural similarity to the S. aureus protein clumping factor A. Study participants received one intramuscular dose of NDV-3A or placebo (adjuvant alone) within 72 h of arrival on base. Longitudinal nasal and oral (throat) swabs were collected throughout the 14-week Infantry training cycle. Safety, immunogenicity, and efficacy of NDV-3A against S. aureus nasal / oral acquisition were the endpoints. RESULTS: The NDV-3A candidate had minimal reactogenicity and elicited robust antigen-specific B- and T-cell responses. During the 56-day post-vaccination period, there was no difference in the incidence of S. aureus nasal acquisition between those who were randomized to receive NDV-3A vs. placebo (25.6% vs. 29.1%; vaccine efficacy [VE]: 12.1%; p = 0.31). In time-to-event analysis, there was no difference between study groups with respect to the S. aureus colonization-free interval (VE: 13%; p = 0.29). Similarly, the efficacy of NDV-3A against S. aureus oral acquisition was poor (VE: 2.4%; p = 0.52). CONCLUSIONS: A single dose of NDV-3A did not prevent nasal nor oral acquisition of S. aureus in a population of military trainees at high risk for colonization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Millar EV, Bennett JW, Barin B, et al. Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees. Vaccine. 2021. PMID: 33962841. doi:10.1016/j.vaccine.2021.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。